Patents Examined by Michael Szperka
  • Antibodies binding to TLR2/TLR4-interacting immunologically active polypeptide
    Patent number: 11435346
    Abstract: Disclosed are immunomodulatory polypeptides that behave as weak TLR2 and TLR4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine TLR2 and TLR4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: September 6, 2022
    Assignee: CDRES PHARMA LLC
    Inventor: Craig D. Scoville
  • Allergen-specific antibodies
    Patent number: 11434282
    Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: September 6, 2022
    Assignees: Chan Zuckerberg Biohub, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Derek Croote, Stephen R. Quake, Kari Nadeau, Spyros Darmanis, David N. Cornfield
  • Anti-CD47 antibodies and uses thereof
    Patent number: 11401329
    Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 2, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou, Joshua Oaks, Haiqun Jia
  • Heterodimeric Fc variants
    Patent number: 11401348
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 2, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Gregory Moore
  • Single-chain chimeric polypeptides and uses thereof
    Patent number: 11401324
    Abstract: Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: August 2, 2022
    Assignee: HCW Biologics, Inc.
    Inventor: Hing Wong
  • Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
    Patent number: 11377504
    Abstract: The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5×10?4 s?1 or more and an association rate constant Ka of 1×104 M?1 s?1 or more.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 5, 2022
    Assignees: National Cancer Center Japan, RIN Institute Inc.
    Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Shinji Saijo, Ryo Tsumura
  • Chimeric factor VIII polypeptides and uses thereof
    Patent number: 11370827
    Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: June 28, 2022
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T Peters, Haiyan Jiang
  • Blood factor monitoring assay and uses thereof
    Patent number: 11372008
    Abstract: The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 28, 2022
    Assignee: Bioverativ Therapeutics Inc.
    Inventor: Jurg Sommer
  • Humanized anti-S100A9 antibody and uses thereof
    Patent number: 11359010
    Abstract: It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: June 14, 2022
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Philippe Tessier, Mélanie Tardif, Traian Sulea
  • Treatment and prevention of cardiovascular disease
    Patent number: 11359011
    Abstract: The methods and compositions described herein improve cardiovascular outcomes using measures related to systemic chronic inflammation (the inflammatory age—iAge, the cardiovascular age—cAge, and levels of certain markers) to stratify patients into low risk and high risk groups. The personalized immune proteome signature creates an individualized initial therapy to reduce cAge and to convert high risk patients into low risk patients. High risk patients can be converted to low risk patients by treating the patients to reduce their cAge, iAge and/or improve their CRS.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 14, 2022
    Assignee: Edifice Health, Inc.
    Inventor: David Furman
  • Anti-SARS-CoV-2 neutralizing antibodies
    Patent number: 11359007
    Abstract: The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: June 14, 2022
    Assignee: NEWSOARA BIOPHARMA CO., LTD.
    Inventors: Yuannian Li, Wenyi Wang
  • Antibodies to LILRB2
    Patent number: 11359019
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: June 14, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Heather B. Cohen, Lauren Pepper Mackenzie, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith
  • Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
    Patent number: 11352438
    Abstract: An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 7, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AG
    Inventors: Koichiro Yoneyama, Christophe Schmitt
  • Treatment of allergic diseases with chimeric protein
    Patent number: 11352443
    Abstract: The present invention provides a chimeric protein comprising: a) a single chain variable fragment (scFv) that binds to a mammalian IgE at an epitope within the amino acid sequence VDGQKATNIFPYTAPGTK (SEQ ID NO:1) of canine IgE or at an epitope within the corresponding amino acid sequence of a different mammalian species; b) a linker peptide; and c) an amino acid sequence comprising an IgE high affinity receptor alpha chain, and methods of use thereof.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 7, 2022
    Assignee: North Carolina State University
    Inventors: Bruce Hammerberg, Sitka Eguiluz-Hernandez, Thierry Olivry
  • Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
    Patent number: 11345759
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: May 31, 2022
    Assignees: CSL Behring GmbH, CSL Ltd
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Patent number: 11345741
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 31, 2022
    Assignee: Vanderbilt University
    Inventors: James E. Crowe, Jr., Seth Zost, Robert Carnahan, Pavlo Gilchuk
  • Shark VNARs for treating COVID-19
    Patent number: 11345742
    Abstract: The present disclosure provides coronavirus S1-fragment specific binding moieties comprising Type II VNAR domains, VNAR antibodies, methods of using those moieties and antibodies to treat COVID-19. In some embodiments, a VNAR antibody, originally selected from a phage display library as a VNAR clone using S1fragments from the SARS-CoV-2 Wuhan strain, are also effective at specifically binding to and/or neutralizing SARS-CoV-2 and certain SARS-CoV-2 mutants.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: May 31, 2022
    Assignee: Ossianix, Inc.
    Inventors: Aziz Gauhar, Cyril V. Privezentzev, Pawel Stocki, Julia Lynn Rutkowski
  • Humanised ADAMTS13 binding antibodies
    Patent number: 11339226
    Abstract: The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Katholieke Universiteit Leuven
    Inventors: Karen Vanhoorelbeke, Shannen F. Deconinck, An-Sofie Schelpe
  • Compositions and methods for treating beta-globinopathies
    Patent number: 11325978
    Abstract: The present invention provides new compositions and methods useful for the treatment and potential cure of beta-globinopathies such as sickle cell disease and beta-thalassemia by inhibiting the expression and/or activity of RIOK3.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: May 10, 2022
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: John Fitzgerald Tisdale, Bjorg Gudmundsdottir, Laxminath Tumburu
  • Bispecific antibodies
    Patent number: 11325983
    Abstract: The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: May 10, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Prafull S. Gandhi, Jens Breinholt, Henrik Oestergaard